An integrated assessment of the clinical safety of artemether-lumefantrine: A new oral fixed-dose combination antimalarial drug

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 94, Issue 4, 2000, Pages 419-424

  Bakshi, R ^a   Hermeling Fritz, I ^a   Gathmann, I ^a   Alteri, E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Artemether; Chemotherapy; Drug combinations; Lumefantrine; Malaria; Plasmodium falciparum; Safety; Side effects; Tolerability

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; CHLOROQUINE; HALOFANTRINE; MEFLOQUINE; PYRIMETHAMINE; QUININE; SULFADOXINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ENDEMIC DISEASE; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MEDICAL ASSESSMENT; MYALGIA; NAUSEA; PLASMODIUM FALCIPARUM; PRURITUS; QT INTERVAL; RASH; SOMNOLENCE; TRAVEL; VERTIGO; VOMITING;

ARTESUNATE; CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0033847345     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(00)90126-3     Document Type: Article

References (24)

1. Neurotoxicity in animals due to arteether and artemether
2. Artemether or artesunate followed by mefloquine as a possible treatment for multidrug resistant falciparum malaria
3. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria
4. Neurotoxicity of artemisinin: Possible counseling and treatment of side-effects
5. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years
6. Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria
7. A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand
8. Cardiac effects of standard-dose halofantrine therapy
9. Ataxia and slurred speech after artesunate treatment for falciparum malaria
10. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice
11. Cardiac effects of antimalarial treatment with halofantrine
12. Mefloquine: A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy
13. Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria
14. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives
15. Pruritus and antimalarial drugs in Africans
16. Treatment of malaria in Vietnam with oral artemisinin
17. Mefloquine treatment of acute falciparum malaria: A prospective study of non-serious adverse effects in 3673 patients
18. The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the tropics to the Netherlands and France
19. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria
20. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria
21. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697
22. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children
23. Averting a malaria disaster
24. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine